ATE300052T1 - Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden - Google Patents
Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptidenInfo
- Publication number
- ATE300052T1 ATE300052T1 AT99958905T AT99958905T ATE300052T1 AT E300052 T1 ATE300052 T1 AT E300052T1 AT 99958905 T AT99958905 T AT 99958905T AT 99958905 T AT99958905 T AT 99958905T AT E300052 T1 ATE300052 T1 AT E300052T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- inhibitors
- radioligands
- amyloid peptide
- peptide production
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10814798P | 1998-11-12 | 1998-11-12 | |
US13128499P | 1999-04-27 | 1999-04-27 | |
PCT/US1999/026715 WO2000028331A1 (en) | 1998-11-12 | 1999-11-12 | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE300052T1 true ATE300052T1 (de) | 2005-08-15 |
Family
ID=26805566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99958905T ATE300052T1 (de) | 1998-11-12 | 1999-11-12 | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden |
Country Status (8)
Country | Link |
---|---|
US (1) | US6331408B1 (de) |
EP (1) | EP1129355B1 (de) |
AT (1) | ATE300052T1 (de) |
AU (1) | AU1618000A (de) |
CA (1) | CA2346099A1 (de) |
DE (1) | DE69926254D1 (de) |
NO (1) | NO20011891L (de) |
WO (1) | WO2000028331A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
CA2346099A1 (en) * | 1998-11-12 | 2000-05-18 | Dupont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
BR9917082A (pt) | 1998-12-24 | 2001-11-06 | Du Pont Pharm Co | Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase |
US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
AU2001239791A1 (en) | 2000-02-17 | 2001-08-27 | Du Pont Pharmaceuticals Company | Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production |
US6713476B2 (en) | 2000-04-03 | 2004-03-30 | Dupont Pharmaceuticals Company | Substituted cycloalkyls as inhibitors of a beta protein production |
WO2001087354A2 (en) * | 2000-05-17 | 2001-11-22 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
BR0106717A (pt) * | 2000-06-01 | 2002-04-16 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos de lactama inovadora |
EP1379634B1 (de) * | 2001-04-20 | 2017-12-13 | The University Of Georgia Research Foundation, Inc. | Inaktivatoren aktiver zentren |
US20090062256A1 (en) * | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
CH698246B1 (de) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
CA2589860A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
EP2261254A3 (de) | 2007-12-21 | 2011-04-13 | Amgen, Inc | Antiamyloide Antikörper und deren Verwendungen |
TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
EP2897954B1 (de) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Fluoralkyl-1,4-benzodiazepinon-verbindungen |
JP2015529253A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Notch阻害剤としてのフルオロアルキルおよびフルオロシクロアルキル1,4−ベンゾジアゼピノン化合物 |
EP2897947B1 (de) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1, 4-benzodiazepinonverbindungen |
EP2897960B1 (de) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Tricyclische/heterocyclische verbindungen als notch-inhibitoren |
JP2015534553A (ja) | 2012-09-21 | 2015-12-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 置換1,5−ベンゾジアゼピノン化合物 |
CN104968648A (zh) | 2012-09-21 | 2015-10-07 | 百时美施贵宝公司 | 1,4-苯并二氮杂*酮化合物的前药 |
TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 |
CN104854097A (zh) | 2012-09-21 | 2015-08-19 | 百时美施贵宝公司 | N-取代的二(氟烷基)-1,4-苯并二氮杂*酮化合物 |
WO2014047370A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
WO2014165718A1 (en) | 2013-04-04 | 2014-10-09 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZW23187A1 (en) * | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
US5252463A (en) * | 1990-06-22 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Clipsin, a chymotrypsin-like protease and method of using same |
GB9022117D0 (en) * | 1990-10-11 | 1990-11-21 | Beecham Group Plc | Novel compounds |
US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
US5538845A (en) * | 1992-02-05 | 1996-07-23 | Athena Neurosciences, Inc. | Beta-amyloid peptide production inhibitors and methods for their identification |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5594006A (en) * | 1993-03-18 | 1997-01-14 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives as matrix metalloproteinases inhibitors |
AU6909194A (en) * | 1993-05-14 | 1994-12-12 | Board Of Regents, The University Of Texas System | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
ZA945719B (en) * | 1993-08-09 | 1996-02-01 | Lilly Co Eli | Identification and use of protease inhibitors |
US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
JPH11507538A (ja) * | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
US5703129A (en) * | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
AU4589297A (en) * | 1996-10-07 | 1998-05-05 | Scios Inc. | Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase |
US5734054A (en) * | 1996-11-05 | 1998-03-31 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
CA2346099A1 (en) * | 1998-11-12 | 2000-05-18 | Dupont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
-
1999
- 1999-11-12 CA CA002346099A patent/CA2346099A1/en not_active Abandoned
- 1999-11-12 DE DE69926254T patent/DE69926254D1/de not_active Expired - Lifetime
- 1999-11-12 AU AU16180/00A patent/AU1618000A/en not_active Abandoned
- 1999-11-12 WO PCT/US1999/026715 patent/WO2000028331A1/en active IP Right Grant
- 1999-11-12 AT AT99958905T patent/ATE300052T1/de not_active IP Right Cessation
- 1999-11-12 EP EP99958905A patent/EP1129355B1/de not_active Expired - Lifetime
- 1999-11-12 US US09/438,901 patent/US6331408B1/en not_active Expired - Lifetime
-
2001
- 2001-04-17 NO NO20011891A patent/NO20011891L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1129355B1 (de) | 2005-07-20 |
DE69926254D1 (de) | 2005-08-25 |
NO20011891L (no) | 2001-07-02 |
US6331408B1 (en) | 2001-12-18 |
WO2000028331A1 (en) | 2000-05-18 |
CA2346099A1 (en) | 2000-05-18 |
EP1129355A1 (de) | 2001-09-05 |
NO20011891D0 (no) | 2001-04-17 |
AU1618000A (en) | 2000-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE300052T1 (de) | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden | |
ATE211129T1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
MY131442A (en) | Excitatory amino acid receptor antagonists | |
ATE224713T1 (de) | Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression | |
ATE491721T1 (de) | Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein- aggregaten | |
MY115977A (en) | Synthetic excitatory amino acids | |
DE60121808D1 (de) | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen | |
EA200401365A1 (ru) | Способы лечения илеуса | |
WO2001087354A3 (en) | Use of small molecule radioligands for diagnostic imaging | |
DE69530933D1 (de) | Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis | |
EP1575989A4 (de) | MIT PrP sp sc/sp WECHSELWIRKENDE MOLEKÜLE UND DEREN VERWENDUNG | |
DE60023860D1 (de) | Verfahren zur herstellung von rekombinanten peptiden | |
RO116898B1 (ro) | Derivaţi de dioxizi de benzotiazină, procedeu pentru prepararea acestora, intermediari, compoziţie farmaceutică şi metodă pentru inhibarea nivelurilor crescute de endotelină | |
DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
DK1373502T3 (da) | Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf | |
NO20051664L (no) | Behandling av demens og Parkinsons sykdom | |
DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
DE60024997D1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
MY120085A (en) | Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines. | |
ATE315582T1 (de) | Verwendung von neuregulin-beta als indikator und/oder target | |
DE69834193D1 (de) | Verfahren zur bestimmung von amyloid-ähnlichen fibrillen oder proteinaggregaten | |
SE0202608D0 (sv) | New sequences | |
WO2003045325A3 (en) | Dopaminergic stimulatory factor | |
TR200003083T2 (tr) | CNS hastalıklarının tedavisi için paroxetine 10-camphorsulfonate. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |